# OGG1 Mutations and Risk of Female Breast Cancer: Meta-Analysis and Experimental Data

Authors: Kashif Ali; Ishrat Mahjabeen; Maimoona Sabir; Humera Mehmood; Mahmood Akhtar Kayani
Journal: Disease Markers
 (2015)

---

## Abstract

In first part of this study association between OGG1 polymorphisms and breast cancer susceptibility was explored by meta-analysis. Second part of the study involved 925 subjects, used for mutational analysis of OGG1 gene using PCR-SSCP and sequencing. Fifteen mutations were observed, which included five intronic mutations, four splice site mutations, two 3′UTR mutations, three missense mutations, and a nonsense mutation. Significantly (p<0.001) increased (~29 fold) breast cancer risk was associated with a splice site variant g.9800972T>G and 3′UTR variant g.9798848G>A. Among intronic mutations, highest (~15 fold) increase in breast cancer risk was associated with g.9793680G>A (p<0.009). Similarly ~14-fold increased risk was associated with Val159Gly (p<0.01), ~17-fold with Gly221Arg (p<0.005), and ~18-fold with Ser326Cys (p<0.004) in breast cancer patients compared with controls, whereas analysis of nonsense mutation showed that ~13-fold (p<0.01) increased breast cancer risk was associated with Trp375STOP in patients compared to controls. In conclusion, a significant association was observed between OGG1 germ line mutations and breast cancer risk. These findings provide evidence that OGG1 may prove to be a good candidate of better diagnosis, treatment, and prevention of breast cancer.


---

## Body

## 1. Introduction

8-Oxoguanine DNA glycosylase 1 (OGG1) is an important protein in base excision repair (BER) pathway which plays a key role in maintaining genome integrity and preventing cancer development [1]. OGG1 is encoded by the OGG1 gene and is an important protein acting as a key enzyme in BER pathway. It initiates the process by recognizing and directly removing 8-hydroxy-2-deoxyguanine (8-OHdG) adducts from damaged DNA by releasing the modified base and generating an AP site [2]. The OGG1 gene is located in chromosome 3p26.2 and this region of genome has frequently been detected missing or deleted in various tumors, particularly lung, colon, stomach, kidney, oesophageal, prostate, and breast tumors, suggesting the loss of OGG1 function as a possible contributor to tumorigenesis and loss of heterozygosity of markers [3]. There are two major isoforms of human OGG1, that is, isoform ∞-OGG1 (345 amino acids) and isoform β-OGG1 (424 amino acids) proteins. The first 316 amino acids are common for both isoforms, while the C-termini vary considerably. OGG1 has two important domains; the OGG-N domain containing mitochondrial localization signal (MLS, position 9–26) partially contributes to the 8-oxoG-binding pocket and the HhH-GPD domain (a helix-hairpin-helix structural element followed by a Gly/Pro-rich loop and a conserved aspartic acid) containing nuclear localization signal (NLS, 335–342) provides both the catalytic and DNA-binding functions of the DNA glycosylase [4]. The human OGG1 protein structure reveals another highly conserved motif which corresponds to the helix-hairpin-helix (HhH) motif and is characteristic of the active site of endonuclease III family of DNA glycosylases/AP lyases [5]. Inactivation of the OGG1 gene may lead to a higher risk of cancer because cells with accumulated 8-OH-G adducts still retain the ability to proliferate and a substantial increase of spontaneous mutation frequencies has been clearly identified in the DNA of mutant mice, bearing transgenic gene when exposed to exogenous carcinogens or endogenous oxidative species [6]. These observations suggest that OGG1 acts as a major protein in pathway responsible for removal of 8-oxoG or 8-OH-G adducts [7].OGG1 gene is highly polymorphic among humans and is also mutated in cancer cells. Epidemiologic studies have linked single nucleotide polymorphisms (SNP) in DNA glycosylase and BER core protein genes to human cancer risk including breast cancer [8, 9]. The OGG1 gene has at least twenty-five validated sequence variants that reportedly change amino acid of the protein but Ser326Cys (rs1052133) has been extensively investigated for its association with different types of cancer risk including esophageal [10], lung [11], stomach [12], thyroid [2], laryngeal [13], colorectal [14, 15], and pancreatic cancer [9]. The results about OGG1 polymorphisms are contradictory and further studies involving different populations are required. Present study is designed to observe the mutational spectrum of OGG1 and its association with different environmental, clinical, and histopathological parameter in breast cancer patients in Pakistani population. Initially a meta-analysis was performed involving previous studies and then the results were compared to obtain a clear picture about the role of OGG1 variations in breast cancer.


## 2. Materials and Methods

### 2.1. Search Strategy and Selection Criteria for Meta-Analysis

A comprehensive literature search was conducted using Pub Med database for all eligible studies (updated from January 2007 to November 2014) reporting OGG1 polymorphism/mutations, using the following search strategy: cancer, OGG1, polymorphisms, mutations, and genetic variations. There was no restriction on sample size, ethnicity of population, language, or type of report. All eligible studies were retrieved and checked for other relevant studies. The literature retrieval was performed in duplication by two independent reviewers. Studies were included only if they met the following criteria: (1) case-control studies which evaluated the association between OGG1 polymorphisms and cancer risk; (2) studies using DNA extracted from blood samples of cancer patients and also from healthy individuals used as controls for comparison; (3) studies using any of the mutation detection techniques (e.g., PCR-RFLP, PCR-SSCP, ARMS-PCR, and qRT-PCR arrays); (4) studies published as full articles in English.A number of studies were excluded on the basis of the following points. (1) Studies using cancer cell lines, tumor samples, serum, or saliva samples were not included. (2) Review articles and previous meta-analysis were also not included. (3) Studies on diseases other than cancer were also excluded from present study.


### 2.2. Collection of Blood Samples

Present study was conducted with a prior approval from ethical committees of both COMSATS Institute of Information Technology Islamabad (CIIT) and collaborating hospitals. A total of 925 subjects were enrolled in present study including 530 female patients with histological confirmed breast cancer and 395 age and ethnicity matched cancer-free healthy female individuals as controls. Patients belonging to different areas of Pakistan were recruited from Nuclear Medicine, Oncology and Radiotherapy Institute (NORI) and Pakistan Institute of Medical Sciences (PIMS), Islamabad Pakistan, while controls were selected randomly and voluntarily from general population. The inclusion criterion for the controls was age and ethnicity matched healthy female individuals with absence of prior history of cancerous or precancerous lesions. Patients and controls suffering from any other familial disease (diabetes, blood pressure, and cardiovascular, renal, or hepatic impairment) were excluded from this study. After obtaining informed and written consent, each individual was personally interviewed using the specifically designed questionnaire. Information regarding age, age at menarche, menopausal status, menopausal age, family history, ethnic group, and tobacco use was collected from both patients and control individuals. Details regarding hormonal receptor status and histopathological findings were also recorded for clinical characterization of patients in first or follow-up meetings. Standard venipuncture was used to collect 5 mL of peripheral blood in EDTA containing tubes from patients and control individuals and was stored at −20°C until further use.


### 2.3. DNA Extraction and Polymerase Chain Reaction (PCR)

Genomic DNA was extracted from leucocytes, using standard phenol-chloroform extraction method as described by Baig et al. [16] with minor alterations. Freshly extracted DNA was quantified by spectrophotometry and yield gel electrophoresis and stored at −20°C till further processing. Human OGG1 exon sequence was taken from Ensemble. Primers were designed using primer 3 software and checked for their specificity using BLAST. Whole coding region including exon intron boundaries of approximately 60 bp sequence of OGG1 was investigated to identify novel, already reported, and any splice site variation. Each PCR reaction was performed in a 10 μL reaction mixture containing 1 μL of genomic DNA (approximately 50 ng) templates, 1 μL (10 mM) of each primer, 1 μL nuclease-free water, and 5 μL PCR master mix (Thermo Scientific) containing 0.05 U/μLTaq DNA polymerase, reaction buffer, 4 mM MgCl2, 0.4 mM of each dNTP. PCR conditions were initial melting step at 94°C for 5 min, 35 cycles each comprised of 94°C for 45 sec, exon specific annealing temperature for 1 min and 72°C for 1 min. It was followed by a final extension step at 72°C for 10 min and finally held at 4°C. 2 μL of PCR products along with loading dye were electrophoresed on a 2% agarose gel and stained with ethidium bromide. 100 bp ladder was also loaded as standard for quantification of amount and confirmation of PCR product size.


### 2.4. Mutational Screening and Sequence Analysis

Single stranded conformational polymorphism (SSCP) assay was used for mutational analysis of PCR products. Samples with altered electrophoretic mobility were reamplified in a separate reaction and were analyzed by direct sequencing to confirm and characterize the nature of mutations/polymorphisms. Control (normal) samples were also sequenced along with cancerous samples to compare the sequencing results. DNA sequencing was carried out by MC lab (USA). Results of DNA sequencing were analyzed using BioEdit software (version 7.0.5) and Alamut visual interactive biosoftware (version 2.4-5).


### 2.5. Data Analysis

χ
2-test, Fisher’s exact test, and Pearson correlation coefficient were used to analyze the differences in selected demographic variables, family history, smoking status, tumor types, tumor grades, ER/PR, and HER-2/nue status by using the Graph Pad Prism 5. Pearson’s correlation coefficient was used to assess the correlations among the observed mutations and clinical and histopathological parameters. Missense mutations were analyzed in silico via Alamut biosoftware (version 2.4-5) for prediction of the pathogenicity caused by point mutations, PhyloP for conservation level of mutated nucleotides, and amino acids along with Grantham distance for physicochemical changes in amino acid structure.


## 2.1. Search Strategy and Selection Criteria for Meta-Analysis

A comprehensive literature search was conducted using Pub Med database for all eligible studies (updated from January 2007 to November 2014) reporting OGG1 polymorphism/mutations, using the following search strategy: cancer, OGG1, polymorphisms, mutations, and genetic variations. There was no restriction on sample size, ethnicity of population, language, or type of report. All eligible studies were retrieved and checked for other relevant studies. The literature retrieval was performed in duplication by two independent reviewers. Studies were included only if they met the following criteria: (1) case-control studies which evaluated the association between OGG1 polymorphisms and cancer risk; (2) studies using DNA extracted from blood samples of cancer patients and also from healthy individuals used as controls for comparison; (3) studies using any of the mutation detection techniques (e.g., PCR-RFLP, PCR-SSCP, ARMS-PCR, and qRT-PCR arrays); (4) studies published as full articles in English.A number of studies were excluded on the basis of the following points. (1) Studies using cancer cell lines, tumor samples, serum, or saliva samples were not included. (2) Review articles and previous meta-analysis were also not included. (3) Studies on diseases other than cancer were also excluded from present study.


## 2.2. Collection of Blood Samples

Present study was conducted with a prior approval from ethical committees of both COMSATS Institute of Information Technology Islamabad (CIIT) and collaborating hospitals. A total of 925 subjects were enrolled in present study including 530 female patients with histological confirmed breast cancer and 395 age and ethnicity matched cancer-free healthy female individuals as controls. Patients belonging to different areas of Pakistan were recruited from Nuclear Medicine, Oncology and Radiotherapy Institute (NORI) and Pakistan Institute of Medical Sciences (PIMS), Islamabad Pakistan, while controls were selected randomly and voluntarily from general population. The inclusion criterion for the controls was age and ethnicity matched healthy female individuals with absence of prior history of cancerous or precancerous lesions. Patients and controls suffering from any other familial disease (diabetes, blood pressure, and cardiovascular, renal, or hepatic impairment) were excluded from this study. After obtaining informed and written consent, each individual was personally interviewed using the specifically designed questionnaire. Information regarding age, age at menarche, menopausal status, menopausal age, family history, ethnic group, and tobacco use was collected from both patients and control individuals. Details regarding hormonal receptor status and histopathological findings were also recorded for clinical characterization of patients in first or follow-up meetings. Standard venipuncture was used to collect 5 mL of peripheral blood in EDTA containing tubes from patients and control individuals and was stored at −20°C until further use.


## 2.3. DNA Extraction and Polymerase Chain Reaction (PCR)

Genomic DNA was extracted from leucocytes, using standard phenol-chloroform extraction method as described by Baig et al. [16] with minor alterations. Freshly extracted DNA was quantified by spectrophotometry and yield gel electrophoresis and stored at −20°C till further processing. Human OGG1 exon sequence was taken from Ensemble. Primers were designed using primer 3 software and checked for their specificity using BLAST. Whole coding region including exon intron boundaries of approximately 60 bp sequence of OGG1 was investigated to identify novel, already reported, and any splice site variation. Each PCR reaction was performed in a 10 μL reaction mixture containing 1 μL of genomic DNA (approximately 50 ng) templates, 1 μL (10 mM) of each primer, 1 μL nuclease-free water, and 5 μL PCR master mix (Thermo Scientific) containing 0.05 U/μLTaq DNA polymerase, reaction buffer, 4 mM MgCl2, 0.4 mM of each dNTP. PCR conditions were initial melting step at 94°C for 5 min, 35 cycles each comprised of 94°C for 45 sec, exon specific annealing temperature for 1 min and 72°C for 1 min. It was followed by a final extension step at 72°C for 10 min and finally held at 4°C. 2 μL of PCR products along with loading dye were electrophoresed on a 2% agarose gel and stained with ethidium bromide. 100 bp ladder was also loaded as standard for quantification of amount and confirmation of PCR product size.


## 2.4. Mutational Screening and Sequence Analysis

Single stranded conformational polymorphism (SSCP) assay was used for mutational analysis of PCR products. Samples with altered electrophoretic mobility were reamplified in a separate reaction and were analyzed by direct sequencing to confirm and characterize the nature of mutations/polymorphisms. Control (normal) samples were also sequenced along with cancerous samples to compare the sequencing results. DNA sequencing was carried out by MC lab (USA). Results of DNA sequencing were analyzed using BioEdit software (version 7.0.5) and Alamut visual interactive biosoftware (version 2.4-5).


## 2.5. Data Analysis

χ
2-test, Fisher’s exact test, and Pearson correlation coefficient were used to analyze the differences in selected demographic variables, family history, smoking status, tumor types, tumor grades, ER/PR, and HER-2/nue status by using the Graph Pad Prism 5. Pearson’s correlation coefficient was used to assess the correlations among the observed mutations and clinical and histopathological parameters. Missense mutations were analyzed in silico via Alamut biosoftware (version 2.4-5) for prediction of the pathogenicity caused by point mutations, PhyloP for conservation level of mutated nucleotides, and amino acids along with Grantham distance for physicochemical changes in amino acid structure.


## 3. Results

In first part of study a meta-analysis was performed to evaluate the association between OGG1 polymorphisms and cancer susceptibility especially as risk factor of breast cancer. Based on our search criteria, 152 studies relevant to the role of OGG1 mutations/polymorphisms on cancer/disease susceptibility were identified. 90 studies of total 152 were excluded on the basis of the following reasons.(i) Five studies were review/meta-analysis, (ii) 8 studies were involving only general healthy population, (iii) 18 studies were involving OGG1 mutations in patients other than cancerous, for example, diabetes, cataract, endometriosis, and so forth, (iv) 14 studies used DNA samples from tissues other than blood samples of cancer patients, and (v) 45 studies were older than January 2007.As a result, a total of 62 relevant studies (involving 32626 individuals including 14844 patients and 17782 healthy control individuals) met the inclusion criteria for the current meta-analysis. Among them, most of studies used PCR-RFLP (48) and other techniques (12) for detection of already reported one polymorphism Ser326Cys in cancer. Only two studies used techniques for the detection of reported as well as novel mutations in cancer, one involved high resolution melting (HRM) analysis and other one used PCR-SSCP. Of all eligible studies, the majority of studies were on head and neck, lung, and colorectal cancers whereas only 6 studies evaluated the OGG1 polymorphism in breast cancer. The majority of studies were from Caucasian (17), Chinese (16), and Indian (14) populations while only one study was from Pakistani population involving head and neck cancer patients. Moreover, only 4 of the available studies used patient sample size more than or equal to 500 and remaining 94% of studies used fewer number of patient samples. Only 3 studies recruited purely population based (PB) controls while all other studies involved hospital based (HB) controls. Findings of all previous studies investigated for this meta-analysis were contradictory regarding association of OGG1 polymorphisms to increased risk of cancer susceptibility. Out of selected 62 studies involving 32626 individuals (including 14844 patients and 17782 controls), thirty-five studies involving 19594 individuals (including 9071 patients and 10523 controls) concluded a contributory role of OGG1 polymorphism to different type of cancers while in twenty-six studies involving 12812 individuals (including 5663 patients and 7149 controls) no association of OGG1 polymorphism to cancer susceptibility was observed and only one study involving 220 individuals (including 110 patients and 110 controls) suggested negative or protective role of OGG1 polymorphism against cancer (Table1). In summary, when all the eligible studies were pooled into the meta-analysis of OGG1 mutations, 60.1% individuals showed an association of OGG1 mutations with different types of cancers while 39.3% individuals showed no association and 0.7% individuals showed a negative or protective role of OGG1 mutations against cancer.Table 1
Literature search in PubMed database for all eligible studies reporting OGG1 polymorphism.
Previous studies with OGG1 germ line mutation analysis
Author and year
Population
Cancer type
Sample size
Source of control
Techniques
Mutations
Cancer risk association
(Location and ethnicity)
Patients
Controls
Arizono et al., 2008 [29]
Asian, Japanese
Bladder cancer
251
251
HB
PCR-RFLP
Ser326Cys
Associated
Bose et al., 2013 [30]
Asian, Indian
Liver cancer
214
210
HB
PCR-RFLP
Ser326Cys
Associated
Canbay et al., 2010 [31]
Caucasian, Turkish
Gastric cancer
40
247
HB/PB
PCR-RFLP
Ser326Cys
Associated
Canbay et al., 2011 [14]
Caucasian, Turkish
Colorectal cancer
79
247
HB
PCR-RFLP
Ser326Cys
Associated
Chang et al., 2009 [32]
Latino-African Americans
Lung cancer
368
579
HB
PCR-RFLP
Ser326Cys
Not associated
Chen et al., 2010 [33]
Asian, Chinese
Pterygium
83
206
HB
TaqMan assays
Ser326Cys
Not associated
Chen et al., 2011 [34]
Asian, Chinese
Breast cancer
518
777
HB
HRM analysis
c.-18G>T, c.-23A>G,
Not associated
c.-53G>C, c.-45G>A, c.-63G>C
Cheng et al., 2012 [35]
Asian, Chinese
Lung cancer
124
126
HB
PCR-RFLP
Ser326Cys
Not associated
Cincin et al., 2012 [36]
Caucasian, Turkish
Endometrial cancer
104
158
HB/PB
PCR-RFLP
Ser326Cys
Associated
Dhillon et al., 2011 [37]
South Australian
Prostate cancer
118
132
HB
PCR-RFLP
Ser326Cys
Associated
Engin et al., 2010 [38]
Caucasian, Turkish
colorectal carcinoma
110
116
HB
PCR-RFLP
Ser326Cys
Not associated
Engin et al., 2011 [39]
Caucasian, Turkish
Gastric cancer
106
116
HB/PB
PCR-RFLP
Ser326Cys
Not associated
Farkasova et al., 2008 [40]
European
Cervical cancer
—
—
HB
PCR-RFLP
Ser326Cys
Not associated
Gangwar et al., 2009 [41]
Asian, North Indian
Urothelial bladder cancer
212
250
HB
PCR-RFLP
Ser326Cys
Associated
García-Quispes et al., 2011 [2]
European, Spanish
Thyroid cancer
402
479
HB/PB
iPLEX
Ser326Cys
Not associated
Jiao et al., 2007 [42]
Asian, Chinese
Gall bladder cancer
204
209
HB
PCR-RFLP
Ser326Cys
Associated
Karahalil et al., 2008 [43]
Caucasian, Turkish
Lung cancer
165
250
HB
PCR-RFLP
Ser326Cys
Not associated
Kim et al., 2013 [44]
Asian, Korean
Breast cancer
346
361
HB
SNP arrays
Ser326Cys
Associated
Kumar et al., 2011 [22]
Asian, Indian
Head and neck cancer
278
278
HB
PCR-RFLP
Ser326Cys
Associated
Laantri et al., 2011 [45]
North African
Nasopharyngeal cancer
598
545
HB
TaqMan assay
Ser326Cys
Not associated
Letkova et al., 2013 [46]
European
Lung cancer
382
379
HB
PCR-RFLP
Ser326Cys
Not associated
Li et al., 2011 [47]
Asian, Chinese
Lung cancer
455
443
HB
PCR-RFLP
Ser326Cys
Associated
Li et al., 2011 [48]
Asian, Chinese
Lymphoblastic leukemia
415
511
HB
TaqMan assay
Ser326Cys
Associated
Li et al., 2013 [49]
Asian, Chinese
Nasopharyngeal cancer
231
300
HB
PCR-RFLP
Ser326Cys
Not associated
Liu et al., 2010 [50]
Asian, Taiwan
Lung cancer
358
716
HB
PCR-RFLP
Ser326Cys
Associated
Luo et al., 2014 [17]
Asian, Chinese
Breast cancer
194
245
HB
PCR-CTPP
Ser326Cys
Not associated
Mahjabeen et al., 2011 [19]
Asian, Pakistani
Head and neck Cancer
300
300
HB/PB
PCR-SSCP
Asp267Asn, Ser279Gly
Associated
Ile253Phe, Ala399Glu
Malik et al., 2010 [51]
Asian, Indian
Gastric Cancer
108
195
HB
PCR-RFLP
Ser326Cys
Not associated
Mandal et al., 2012 [52]
Asian, Indian
Prostate cancer
192
224
HB/PB
PCR-RFLP
Ser326Cys
Not associated
Hsu et al., 2010 [53]
Asian, Chinese
Breast cancer
401
533
HB
PCR-RFLP
Ser326Cys
Associated
Mitra et al., 2011 [54]
Asian, Indian
Head and neck cancer
350
225
HB
PCR-RFLP
Ser326Cys
Associated
Mittal et al., 2012 [55]
Asian, Indian
Prostate cancer
195
250
PB
ARMS-PCR
Ser326Cys
Associated
Mittal et al., 2012 [55]
Asian, Indian
Bladder cancer
212
250
PB
ARMS-PCR
Ser326Cys
Associated
Narter et al., 2009 [56]
Caucasian, Turkish
Bladder cancer
83
45
HB
PCR-RFLP
Ser326Cys
Not associated
Ouyang et al., 2013 [57]
Asian, Chinese
lung adenocarcinoma
82
201
HB
PCR-RFLP
Ser326Cys
Not associated
Park et al., 2007 [58]
Asian, Korean
Colorectal cancer
439
676
HB
Sequencing
Ser326Cys
Not associated
Pawlowska et al., 2009 [59]
European, Polish
Laryngeal cancer
253
253
HB
PCR-RFLP
Ser326Cys
Associated
Przybylowska et al., 2013 [60]
Caucasian Polish
Colorectal cancer
182
245
HB/PB
PCR-RFLP
Ser326Cys
Associated
Ramaniuk et al., 2014 [61]
Russian, Belarus
Colorectal
336
370
HB
PCR-RFLP
Ser326Cys
Associated
Reeves et al., 2012 [62]
Australian/Polish
Colorectal cancer
209
215
HB
RT-PCR
Ser326Cys
Not associated
Romanowicz-Makowska et al., 2008 [63]
Caucasian, Polish
Breast cancer
100
106
HB
PCR-RFLP
Ser326Cys
Not associated
Romanowicz-Makowska et al., 2011 [64]
European, Polish
Endometrial cancer
150
150
HB
PCR-RFLP
Ser326Cys
Not associated
de Ruyck et al., 2007 [65]
European, Belgian
Lung cancer
110
110
HB
PCR-RFLP
Ser326Cys
Negatively associated
Sameer et al., 2012 [66]
Asian, Indian
Colorectal cancer
114
200
HB
PCR-RFLP
Ser326Cys
Not associated
Sangrajrang et al., 2008 [67]
Asian, Thai
Breast cancer
507
425
HB
Melting curve analysis
Ser326Cys
Associated
Santonocito et al., 2012 [68]
European, Italian
Melanoma
167
186
HB
PCR-RFLP
Ser326Cys
Not associated
Santos et al., 2012 [69]
Caucasian
Thyroid cancer
109
217
HB
PCR-RFLP
Ser326Cys
Not associated
Sliwinski et al., 2011 [70]
Caucasian Polish
Head and neck cancer
265
280
HB
PCR-RFLP
Ser326Cys
Associated
Sliwinski et al., 2009 [71]
Caucasian, Polish
Colorectal cancer
100
100
HB
PCR-RFLP
Ser326Cys
Associated
Sobczuk et al., 2012 [72]
Caucasian, Polish
Endometrial Cancer
94
14
HB
PCR-RFLP
Ser326Cys
Not associated
Srivastava et al.,  2010 [73]
Asian, Indian
Gall bladder cancer
230
230
PB
PCR-RFLP
Ser326Cys
Associated
Srivastava et al., 2009 [74]
Asian, Indian
Gall bladder cancer
173
204
HB
PCR-RFLP
Ser326Cys
Associated
Stanczyk et al., 2011 [75]
Caucasian, Polish
Acute lymphoblastic leukemia
97
131
HB
PCR-RFLP
Ser326Cys
Associated
Sun et al., 2010 [76]
Asian, Chinese
Gastric cancer
73
255
HB
PCR-RFLP
Ser326Cys
Associated
Upadhyay et al., 2010 [77]
Asian, Indian
Esophageal cancer
335
402
HB
PCR-RFLP
Ser326Cys
Not associated
Wang et al., 2011 [78]
Asian, Taiwanese
Urothelial carcinoma
460
540
HB
PCR-RFLP
Ser326Cys
Associated
Xue et al., 2013 [79]
Asian, Chinese
Lung adenocarcinoma
410
410
HB
PCR-RFLP
Ser326Cys
Associated
Yang et al., 2008 [80]
Asian, Chinese
Laryngeal cancer
72
72
HB
PCR-RFLP
Ser326Cys
Associated
Yuan et al., 2012 [81]
Asian, Chinese
Hepatocellular cancer
350
400
HB
PCR-RFLP
Ser326Cys
Associated
Yun et al., 2012 [82]
Asian, Korean
Prostate cancer
266
266
HB
PCR-RFLP
Ser326Cys
Associated
Zhang et al., 2010 [83]
American
Prostate cancer
193
197
HB/PB
Mass  spectrometry
Ser326Cys
Associated
Zhao et al., 2011 [84]
Asian, Chinese
Renal cell carcinoma
572
574
HB
TaqMan Assay
Ser326Cys
AssociatedSecond part of present study involved 925 subjects including 530 breast cancer patients and 395 cancer-free healthy individuals as control used for mutational analysis of OGG1 gene. Mean age of patients and controls was calculated as 46.4 (±11.59) and 42.80 (±12.96) years, respectively (see Supplementary Tables 1 and 2 in Supplementary Material available online athttp://dx.doi.org/10.1155/2015/690878). In present study, all (eight) exons of OGG1 were screened comprehensively for any novel or reported germline mutations involving SSCP followed by direct sequence analysis of suspected samples. Fifteen different types of mutations were observed, which included five intronic, four splice site, two 3′UTR, and four missense mutations. Among identified mutations, one intronic mutation (g.9793680G>A, rs55846930) and two missense mutations (Gly221Arg, TMP_ESP_3_9796483 and Ser326Cys, rs1052133) have already been reported while remaining twelve mutations were novel. Four novel mutations (g.9792260 insert_T; g.9793748G>A; g.9798336T>G; g.9798349T>A) were observed in intronic regions, four mutations (g.9792109delT, g.9798307T>G, g.9798502T>G & g.9800972T>G) were observed in splice site regions, two mutations (g.9798848G>A, g.9798896T>C) were observed in 3′UTR, one missense mutation (g.9793544T>G, Val159Gly) was observed in exon 3, and one nonsense mutation (g.9807669G>A, Trp375STOP) was observed in exon 8 (Figure 1).Figure 1
Sequencing electropherogram of polymorphisms of OGG1. (a), (b), (c), (d), and (e) are intronic mutations ((a) g.9792260 insertion of T in Intron 1, (b) g.9793680G>A (rs55846930) substitution in Intron 3, (c) g.9793748G>A substitution in Intron 3, (d) g.9798336T>G substitution in Intron 5, and (e) g.9798349T>A substitution in Intron 5). (f), (g), (h), and (i) are splice site mutations ((f) g.9792109 deletion of T at Splice site region of Intron 1, (g) g.9798307T>G substitution in splice site region of Intron 5, (h) g.9798502T>G substitution in splice site region of Intron 6, and (i) g.9800972T>G substitution in splice site region of Intron 7a). (j) and (k) are substitutions in 3′UTR ((j) g.9798848G>A substitution in 3′UTR (k) g.9798896T>C substitution in 3′UTR). (l), (m), (n), and (o) are missense mutations ((l) missense mutation Val159Gly showing g.9793544T>G substitution in Exon 3 resulting in change of codon from GTG to GGG encoding amino acid Valine instead of Glycine, (m) missense mutation Gly221Arg (TMP_ESP_3_9796483) showing g.9796483G>A substitution in Exon 4 resulting in change codon from GGG to AGG encoding the amino acid Glycine instead of Arginine, (n) missense mutation Ser326Cys (rs1052133) (CM993185) showing g.9798773C>G substitution in Exon 6d resulting in change of codon from TCC to TGC encoding the amino acid Serine instead of Cysteine, and (o) nonsense mutation Trp375STOP∗ showing g.9807669G>A substitutions in Exon 8 resulting in change of codon from TGG to TGA terminating the protein instead of encoding the Tryptophan amino acid).
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)
(j)
(k)
(l)
(m)
(n)
(o)Significantly increased breast cancer risk was found associated with different mutations when compared with controls (Table2). Three intronic mutations (g.9792260 insert_T; g.9798336T>G; and g.9798349T>A) and one 3′UTR mutation (g.9798896T>C) were also detected in control samples but their frequency was significantly high in patients (p<0.05). Significantly (p<0.001) increased (~29 fold) breast cancer risk was found associated with a splice site variant g.9800972T>G (OR = 28.85, 95% CI = 3.87 to 207.7) and 3′UTR variant g.9798848G>A (OR = 29.20, 95% CI = 33.98 to 213.74). Among intronic mutations, highest (~15 fold) increase in breast cancer risk was associated with g.9793680G>A variation (OR = 14.65, 95% CI = 1.95 to 109.9; p<0.009). Similar trend was observed in all detected missense mutations in breast cancer patients when compared with controls and ~14-fold increased risk was associated with Val159Gly (OR = 13.68, 95% CI = 1.82 to 102.9; p<0.01), ~17-fold with Gly221Arg (OR = 16.85, 95% CI = 2.26 to 125.53; p<0.005), and ~18-fold with Ser326Cys (OR = 18.45, 95% CI = 2.49 to 136.99; p<0.004) in breast cancer patients compared with controls, whereas analysis of nonsense mutation showed that ~13-fold (OR = 12.90, 95% CI = 1.71 to 97.28; p<0.01) increased breast cancer risk was associated with Trp375STOP in patients compared to controls.Table 2
Mutations and their allele frequencies observed in the OGG1 gene in breast cancer patients.
Mutation/exonChr3 (GRCh37)
Patients
Controls
aOdds ratio (95% CI)
bp value
Number
Allele frequencyMinor/major
Number
Allele frequencyMinor/major
g.9792260 insert_T Intron 1
34
T 0.09/0.91
07
T 0.35/0.65
3.80 (1.67 to 8.66)
0.001
g.9793680G>A Intron 3 (rs55846930)
19
A 0.05/G 0.95
00
A 00/G 1.0
14.65 (1.95 to 109.90)
0.009
g.9793748G>A Intron 3
14
A 0.04/G 0.96
00
A 00/G 1.0
10.70 (1.40 to 81.64)
0.02
g.9798336T>G Intron 5
10
G 0.03/T 0.97
06
G 0.40/T 0.60
1.25 (0.45 to 3.46)
0.67
g.9798349T>A Intron 5
34
A 0.09/T 0.91
02
A 0.10/T0.90
13.30 (3.18 to 55.70)
0.0004
g.9792109delT splice site Intron 1
26
0.07/T 0.93
00
00/T 1.0
20.07 (2.71 to 148.53)
0.003
g.9798307T>G splice site Intron 5
16
G 0.04/T 0.96
00
G 00/T 1.0
12.11 (1.60 to 91.70)
0.01
g.9798502T>G splice site Intron 6
18
G 0.05/T 0.95
00
G 00/T 1.0
13.68 (1.82 to 102.90)
0.01
g.9800972T>G splice site intron 7a
36
G 0.10/T 0.90
00
G 00/T 1.0
28.85 (3.87 to 207.70)
0.001
g.9798848G>A 3′UTR
37
A 0.10/G 0.90
00
A 00/G 1.0
29.20 (3.98 to 213.74)
0.001
g.9798896T>C 3′UTR
48
C 0.13/T 0.87
03
C 0.15/T 0.85
12.85 (3.97 to 41.56)
<0.0001
g.9793544T>G Exon 3, Val159Gly
18
G 0.05/T 0.95
00
G 00/T 1.0
13.68 (1.82 to 102.90)
0.01
g.9796483G>A Exon 4, Gly221Arg (TMP_ESP_3_9796483)
22
A 0.06/G 0.94
00
A 00/G 1.0
16.85 (2.26 to 125.53)
0.005
g.9798773C>G Exon 6d Ser326Cys (rs1052133) (CM993185)
24
G 0.06/C 0.94
00
G 00/C 1.0
18.45 (2.49 to 136.99)
0.004
g.9807669G>A Exon 8, Trp375STOP
17
A 0.05/G 0.95
00
A 00/G 1.0
12.90 (1.71 to 97.28)
0.01
OR: odds ratio; CI: confidence interval.aORs for logistic regression analysis. bp<0.05, by χ2-test for trend.Missense mutations Val159Gly, Gly221Arg, and Ser326Cys were observed in protein domains HhH-GPD and 8-oxoguanine DNA-glycosylase (Supplementary Table 3). Missense and nonsense mutations were also analyzed via Alamut biosoftware (version 2.4.5) to check the conservation levels of mutated nucleotides and amino acids along with in silico predictions about Align GVGD score, Grantham distance, SIFT score and Mutation Taster (Table3). Mutation Taster predicted two missense mutations (Val159Gly and Gly221Arg) and one nonsense mutation (Trp375STOP) as potentially disease causing (p=1.0). Greater physiochemical difference in protein structure was predicted in case of nonsense mutation Trp375STOP that resulted in truncated protein chain due to replacement of a moderately conserved amino acid Tryptophan with a stop codon (Grantham distance = 170). Protein modeling of two detected mutations (Val159Gly, Gly221Arg) of OGG1 and comparison with wild-type OGG1 protein has concluded that no major conformational change occurs due to these mutations while one nonsense mutation (Trp375STOP) resulted in truncation of protein (Figure 2).Table 3
Mutations in OGG1 gene in breast cancer patients with conservation score, SIFT score, Align GVGD score, Grantham distance, and Mutation Taster prediction.
Change in nucleotidewith its conservation level PhyloP score [−14.1; 6.4]
Change in  codon
Amino acid changewith its conservation level (up to 13 species)
SIFT score(median)
Align GVGD score(C0–C65)
Grantham dist. (for physicochemical difference b/w amino acids)(0–215)
Mutation Taster (p value)
g.9793544T>G Highly conserved nucleotide phyloP: 4.97
GTG to GGG
Val159Gly Moderately conserved amino acid
Deleterious 0.01 (2.95)
C0 (GV: 197.52-GD: 72.75)
109 (moderate)
Disease causing(p=1.0)
g.9796483G>A Moderately conserved nucleotide phyloP: 2.38
GGG to AGG
Gly221Arg Moderately conserved amino acid
Tolerated 0.28 (2.95)
C0 (GV: 161.50-GD: 19.25
125 (moderate)
Disease causing(p=0.999)
g.9798773C>G Not conserved nucleotide phyloP: 0.28
TCC to TGC
Ser326Cys Weakly conserved amino acid
Tolerated 0.19 (2.95)
C0 (GV: 353.86-GD: 0.00)
112 (moderate)
Polymorphism (p=1.0)
g.9807669G>A Weakly conserved nucleotide phyloP: 0.12
TGG to TGA
Trp375STOP Moderately conserved amino acid
Deleterious 0.01 (2.95)
C0 (GV: 197.52-GD: 72.75)
170 (large)Protein truncation
Disease causing(p=1.0)
PhyloP was used as a conservation score rating the nucleotides from “not conserved” (−14.1) to “highly conserved” (6.4).  Align GVGD score: most likely deleterious (C65) to least likely deleterious (C0) GV (Grantham variation) and GD (Grantham deviation). The Grantham distance was used to evaluate physicochemical changes in amino acids (0 = no physicochemical changes; 215 = large changes). In silico predictions were performed using PolyPhen-2 (Polymorphism Phenotyping-2), SIFT (Sorting Intolerant from Tolerant) score: <0.05 deleterious, >0.05 tolerated, and Mutation Taster: disease causing variants (p value = 1.0), might not be disease causing (p value <0.99).Figure 2
Superimposed protein structure of mutated OGG1 with its wild type. Wild-type OGG1 protein (grey) and mutated OGG1 protein (blue). Superimposed structure of mutated OGG1 protein showing the location of two observed mutations, Val159Gly and Gly221Arg. Wild-type protein model obtained from protein data bank. Structure was predicted using automated Swiss model. Two structures, wild and mutated, were aligned using UCSF chimera software.Association of observed mutations was also correlated with different clinicopathological parameters including family history, menopausal age, and HER-2/nue and ER/PR status. Frequency of OGG1 mutations was observed to be significantly higher in patients with invasive ductal carcinoma (p<0.0001), negative ER (p<0.001), and negative PR status (p<0.01). All observed OGG1 mutations were found significantly correlated with tumor types (r=-0.333∗∗∗; p<0.0001), ER status (r=0.739∗∗; p<0.001), and PR status (r=-0.155∗; p<0.01) of breast cancer patients but a nonsignificant correlation was observed between all mutations and HER-2/neu status (r=0.318, p=0.12) of breast cancer patients (Table 4). As shown in Table 5, significantly increased breast cancer risk was associated with an intronic (g.9793680G>A, p<0.03), a splice site (g.9798502T>G, p<0.03), and a missense (Ser326Cys, p<0.009) mutation in patients with family history as compared to controls. Correlations between frequency of OGG1 mutations and menopausal age of breast cancer patients (Table 5) revealed that frequencies of three intronic mutations (g.9792260 ins_T; g.9793680G>A; and g.9798349T>A), two splice site mutations (g.9792109delT and g.9800972T>G), two 3′UTR mutations (9798848G>A and g.9798896T>C), and one missense mutation (Ser326Cys) were significantly higher (p<0.05) in patients with earlier menopause (≤50 years) compared to controls and patients with late menopause (>50 years). Table 6 showed association of OGG1 mutations with smoking status of patients and controls. Statistically significant (p<0.05) association of OGG1 mutations (Ser326Cys, g.9792109delT, g.9800972T>G, g.9792260 ins_T, and g.9798848G>A) was observed with patients having smoking history compared to patients and controls with no smoking history.Table 4
Correlation between OGG1 mutations and tumor types, ER/PR status, and HER-2/neu status in breast cancer patients.
Mutation/exonChr3 (GRCh37)
Type of tumor
ER status
PR status
HER-2/neustatus
DCIS
IDC
ILC
−ve
+ve
−ve
+ve
−ve
+ve
Number (%)
Number (%)
Number (%)
Number (%)
Number (%)
Number (%)
Number (%)
Number (%)
Number (%)
g.9792260 insert_T Intron 1
6 (7.69)
24 (11.11)
4 (10.25)
20 (9.57)
12 (10.62)
28 (13.66)
6 (4.96)
24 (14.46)
9 (7.44)
g.9793680G>A Intron 3 (rs55846930)
9 (11.54)
8 (3.70)
2 (5.13)
10 (4.78)
9 (7.96)
16 (7.8)
2 (1.65)
15 (9.14)
4 (3.3)
g.9793748G>A Intron 3
8 (10.25)
5 (2.31)
1 (2.56)
10 (4.78)
4 (3.35)
5 (2.43)
9 (7.44)
7 (4.27)
7 (5.78)
g.9798336T>G Intron 5
00
6 (2.77)
4 (10.25)
6 (2.87)
3 (2.65)
8 (3.9)
2 (1.65)
5 (3.04)
4 (3.3)
g.9798349T>A Intron 5
8  (10.25)
21 (9.72)
5 (12.82)
18 (8.61)
13 (11.50)
21 (10.24)
13 (10.74)
16 (9.76)
13 (10.74)
g.9792109delT splice site Intron 1
4 (5.13)
16 (7.4)
6 (15.38)
16 (76.55)
10 (10.62)
18 (8.78)
8 (6.61)
17 (10.36)
12 (9.91)
g.9798307T>G splice site Intron 5
6 (7.69)
10 (4.63)
00
9 (4.30)
7 (6.19)
09 (4.39)
6 (4.96)
8 (4.87)
6 (4.96)
g.9798502T>G splice site Intron 6
4 (5.13)
11 (5.09)
3 (7.69)
16 (76.55)
2 (2.21)
9 (4.39)
9 (7.44)
12 (7.32)
6 (4.96)
g.9800972T>G splice site intron 7a
3 (3.85)
28 (12.96)
1 (2.56)
19 (9.09)
13 (11.50)
14 (6.82)
16 (13.22)
13 (7.93)
16 (13.22)
g.9798848G>A 3′UTR
00
30 (13.89)
3 (7.69)
24 (11.48)
13 (11.50)
16 (7.8)
13 (10.74)
16 (9.76)
8 (6.61)
g.9798896T>C 3′UTR
8 (10.25)
17 (4.63)
5 (12.82)
29 (13.87)
14 (12.38)
11 (5.36)
12 (9.91)
15 (9.14)
11 (9.09)
g.9793544T>G Exon 3, Val159Gly
4 (5.13)
14 (6.48)
00
12 (5.65)
6 (5.30)
16 (7.8)
2 (1.65)
3 (1.83)
12 (9.91)
g.9796483G>A Exon 4, Gly221Arg (TMP_ESP_3_9796483)
5 (6.41)
14 (6.48)
2 (5.13)
15 (7.18)
5 (4.42)
10 (4.87)
8 (6.61)
7 (4.27)
6 (4.96)
g.9798773C>G Exon 6d Ser326Cys (rs1052133) (CM993185)
6 (7.69)
15 (6.94)
1 (2.56)
12 (5.65)
8 (7.08)
19 (9.27)
3 (2.48)
6 (3.66)
7 (5.78)
g.9807669G>A Exon 8 Trp375STOP
7 (8.97)
4 (1.85)
2 (5.13)
9 (4.30)
7 (6.19)
5 (2.28)
14 (11.57)
7 (4.27)
6 (4.96)
Correlationa
-
0.333
∗
∗
∗
0.739
∗
∗
-
0.155
∗
0.318
p valueb
0.0001
0.001
0.01
0.12
aPearson correlation coefficient; bp value for χ2 test; p<0.05 is considered statistically significant; IDC: invasive ductal carcinoma; DCI: ductal carcinoma in situ; ILC: invasive lobular carcinoma; ER: estrogen receptor; PR: progesterone receptor; HER-2/nue: human epidermal growth factor receptor 2. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.Table 5
Association of OGG1 mutations with family history and menopausal age in breast cancer patients in present study.
Mutation/exonChr3 (GRCh37)
Family history of cancer
Menopause at ≤50 years
Menopause at  >50 years
Patients (%)
Control (%)
OR (95% CI),p value
Patients (%)
Control (%)
OR (95% CI),p value
Patients (%)
Control (%)
OR (95% CI),p value
g.9792260 ins_T  Intron 1
8  (8.2)
02  (40)
3.0  (0.6 to 14.3), 0.1
17 (11.0)
4 (36.4)
3.2 (1.1 to 9.6),0.04
5 (11.1)
2 (25)
1.8 (0.3 to 9.4), 0.4
g.9793680G>A Intron 3  (rs55846930)
12 (12.2)
0
9.1 (1.2 to 70.5),0.03
11 (7.1)
0
8.2 (1.0 to 64.0),0.05
4 (8.8)
0
2.9 (0.3 to 26.1), 0.3
g.9793748G>A Intron 3
5 (5.1)
0
3.7 (0.4 to 32.2), 0.2
10 (6.5)
0
7.4 (0.9 to 58.5), 0.06
4 (8.8)
0
2.9 (0.3 to 26.1), 0.3
g.9798336T>G Intron 5
6 (6.1)
01 (20)
4.5 (0.5 to 37.6), 0.1
08 (5.2)
2 (18.2)
2.9 (0.6 to 13.9), 0.2
2 (4.4)
2 (25)
0.7 (0.1 to 5.1), 0.7
g.9798349T>A Intron 5
6 (6.1)
01 (20)
4.5 (0.5 to 37.6), 0.1
19 (12.3)
01 (9.9)
14.6 (1.9 to 110.5),0.009
4 (8.8)
1 (12.5)
2.9 (0.3 to 26.1), 0.3
g.9792109delT splice site Intron 1
4 (4.1)
0
3.0 (0.3 to 26.9), 0.3
13 (8.4)
0
9.8 (1.3 to 75.3),0.03
1 (2.2)
0
0.7 (0.04 to 11.5), 0.8
g.9798307T>G splice site Intron 5
2 (2.0)
0
1.5 (0.1 to 16.5), 0.7
06 (5.2)
0
4.4 (0.5 to 36.6), 0.2
4 (8.8)
0
2.9 (0.3 to 26.1), 0.3
g.9798502T>G splice site Intron 6
12 (12.2)
0
9.1 (1.2 to 70.5),0.03
06 (5.2)
0
4.4 (0.5 to 36.6), 0.2
3 (6.6)
0
2.2 (0.2 to 20.9), 0.5
g.9800972T>G splice site Intron 7a
0
0
00
16 (10.3)
0
12.2 (1.6 to 92.7),0.02
6 (13.2)
0
4.4 (0.5 to 36.6), 0.2
g.9798848G>A 3′UTR
5 (5.1)
0
3.7 (0.4 to 32.2), 0.2
14 (9.0)
0
10.6 (1.4 to 81.1),0.02
3 (6.6)
0
2.2 (0.2 to 20.9), 0.5
g.9798896T>C 3′UTR
9 (9.2)
01 (20)
6.8 (0.8 to 54.0), 0.07
16 (10.3)
01 (9.9)
12.2 (1.6 to 92.7),0.02
3 (6.6)
1 (12.5)
2.2 (0.2 to 20.9), 0.5
g.9793544T>G Exon 3, Val159Gly
4 (4.1)
0
3.0 (0.3 to 26.9), 0.3
02 (1.3)
0
1.4 (0.1 to 15.9), 0.8
1 (2.2)
0
0.7 (0.04 to 11.5), 0.8
g.9796483G>A Exon 4, Gly221Arg (TMP_ESP_3_9796483)
2 (2.0)
0
1.5 (0.1 to 16.5), 0.7
04 (2.6)
0
2.9 (0.3 to 26.1), 0.3
2 (4.4)
0
1.4 (0.1 to 15.9), 0.8
g.9798773C>G Exon 6d, Ser326Cys (rs1052133) (CM993185)
19 (19.4)
0
14.6 (2.0 to 109.9),0.009
13 (8.4)
0
9.8 (1.3 to 75.3),0.03
3 (6.6)
0
2.2 (0.2 to 20.9), 0.5
g.9807669G>A Exon 8 Trp375STOP
4 (4.1)
0
3.0 (0.3 to 26.9), 0.3
08 (5.2)
0
5.9 (0.7 to 47.5), 0.1
1 (2.2)
0
0.7 (0.04 to 11.5), 0.8
OR: odds ratio; CI: confidence interval. ORs for logistic regression analysis.p<0.05, by χ2-test for trend.Table 6
Distribution and association of OGG1 mutations with smoking status in breast cancer patients.
Mutation/exonChr3 (GRCh37)
Patients
Smokers (%)
Nonsmokers (%)
ORa (95%CI), bp value
g.9792260 ins_T  Intron 1
4  (4.6)
30  (12.4)
0.34  (0.12 to 1.0),0.05
g.9793680G>A  Intron 3   (rs55846930)
5  (5.7)
14  (5.8)
1.0  (0.35 to 2.84), 1.0
g.9793748G>A Intron 3
1 (1.1)
13  (5.4)
0.2  (0.03 to 1.59), 0.13
g.9798336T>G Intron 5
2 (2.3)
08  (3.3)
0.7  (0.14 to 3.31), 0.64
g.9798349T>A Intron 5
5  (5.7)
29  (12.0)
0.45  (0.17 to 1.19), 0.1
g.9792109delT splice site Intron 1
14 (16.1)
12  (5.0)
3.67  (1.6 to 8.3),0.002
g.9798307T>G Splice site Intron 5
0
16  (6.6)
0.16  (0.02 to 1.26), 0.08
g.9798502T>GSplice site Intron 6
2 (2.3)
16  (6.6)
0.33  (0.07 to 1.48), 0.1
g.9800972T>G Splice site Intron 7a
15  (17.2)
21  (8.7)
2.19  (1.07 to 4.48),0.03
g.9798848G>A 3′UTR
4  (4.6)
33  (7.8)
0.3  (0.1 to 0.88),0.03
g.9798896T>C 3′UTR
09 (10.3)
39  (16.1)
0.6  (0.28 to 1.3), 0.2
g.9793544T>G Exon 3, Val159Gly
2 (2.3)
16  (6.6)
0.3  (0.07 to 1.47), 0.15
g.9796483G>A Exon 4, Gly221Arg (TMP_ESP_3_9796483)
4  (4.6)
18  (7.4)
0.6  (0.2 to 1.8), 0.3
g.9798773C>G Exon 6d, Ser326Cys(rs1052133) (CM993185)
17 (19.5)
07  (2.9)
8.1  (3.2 to 20.4),<0.0001
g.9807669G>A Exon 8 Trp375STOP
3 (3.4)
14 (5.8)
0.6  (0.16 to 2.1), 0.4
aOR: odds ratio; CI: confidence interval. aORs for logistic regression analysis. bp<0.05 is considered statistically significant, by χ2-test for trend.


## 4. Discussion

OGG1 is an important gene of BER pathway which encodes the enzyme responsible for the excision of 8-oxoguanine (8-oxoG), a mutagenic base byproduct which occurs as a result of exposure to reactive oxygen species (ROS) [11]. In first part of study a meta-analysis was designed to explore the association between OGG1 polymorphisms and breast carcinogenesis. Results of current meta-analysis revealed that 60 out of 62 selected studies focused only on OGG1 mutation (Ser326Cys) for its role in carcinogenesis and the majority of studies (60%) concluded association of this mutation with different cancers (Table 1). But mutations other than Ser326Cys, in the same domain or other domains of OGG1 singly or in combination may also be important in initiation and development of cancer as reported by Mahjabeen et al. [13]. Moreover studies involving relatively larger population for exploration of different OGG1 mutations (novel as well as reported) in relation to other clinicohistopathological parameters may also be needed for their role in cancer development.Second part of present study is designed to screen all intronic and exonic regions of OGG1 gene in 925 individuals including 530 breast cancer patients and 395 controls using PCR-SSCP followed by sequencing. A total of fifteen mutations were identified in patients and in some control individuals. Eleven mutations were observed in different noncoding regions of OGG1 gene including five mutations in intronic regions, four mutations in donor splice site, and two mutations in 3′UTR regions. Among these, 12 mutations were novel and three were already reported (rs55846930, TMP_ESP_3_9796483, and rs1052133). Frequencies of these observed spice site mutations were found significantly higher in patients as compared to control individuals suggesting their association with breast carcinogenesis. Observed mutations were also analyzed by Alamut biosoftware (version 2.4-5) which predicted that skip of Exons 1, 5, 6, and 7 is very likely as mutations were observed in donor splice site areas of respective exons. Since splice site regions in a gene are involved in the processing of precursor mRNA into mature mRNA and deletion, insertion, or any substitution in the splice sites results in immature mRNA which may have one or more introns in it, leading to the production of aberrant proteins [17]. So mutations in these regions may be very crucial for cellular functioning.In addition to these, three missense mutations (Val159Gly, Gly221Arg, and Ser326Cys) and a nonsense mutation (Trp375STOP) were also found significantly higher in breast cancer patients compared to control individuals suggesting their association with breast carcinogenesis. Among these, two missense mutations (Val159Gly in Exon 3 and Gly221Arg in Exon 4) were found in the HhH-GPD domain. HhH-GPD domain of OGG1 is much important as it performs the catalytic as well as DNA-binding functions of the DNA glycosylase so mutations in this domain might be pathogenic [18]. In this study another missense mutation, Ser326Cys, was also observed mainly as homozygous genotype. This mutation has already been extensively investigated and found to be associated in different types of cancers [9, 19]. Ser326Cys variant is located in 8-oxoguanine DNA-glycosylase domain, which is involved in DNA glycosylase activity of OGG1 protein [4]. Cells with Ser326Cys mutation in homozygous condition are reported to be much deficient in the repair of oxidative DNA damage especially when they are under excessive oxidative stress [20]. In addition to these, a nonsense mutation Trp375STOP was also observed in the C-terminus of β isoform of OGG1 protein resulting in truncation of protein which might compromise the proper functioning of OGG1 protein. Function of this specific region of C-terminus of β isoform of OGG1 is still not perfectly clear as it has been least investigated, whereas presence of long coiled tail, spanning a transmembrane domain in the C-terminus of β isoform of OGG1 protein, suggests its clear role in anchoring the protein in membranous structures [4].Missense and nonsense mutations observed in this study were analyzed via Alamut biosoftware (version 2.4-5) and observed that missense mutations especially of highly conserved nucleotides (g.9793544T>G) and conserved amino acids (Val159Gly; Gly221Arg; and Trp375STOP) have shown some deleterious, potentially disease causing effects resulting physiochemical alterations in structure of amino acids. In silico predictions about mutations using PolyPhen-2 [21], SIFT [22], and Mutation Taster [23] software have previously been considered an important tool in exploration of possible effects of mutations and similar results were achieved by Alamut software in this study.OGG1 mutation frequencies were also correlated with different clinicopathological parameters and significant findings were observed. Higher mutation frequencies were found to be associated with invasive ductal carcinoma, family history of cancer, early menopause, smoking history, and negative ER, PR, and HER-2/neu status which have been reported to contribute in breast cancer development in Pakistani populations [24, 25] and worldwide [25, 26]. Use of tobacco has been considered a well-known environmental risk factor of various cancers. Reactive oxygen species present in tobacco smoke produce 8-hydroxyguanine (8OH-G), which may cause oxidative DNA damage. The OGG1 protein is in front line of the cellular defense against oxidative DNA damage and to repair the 8-oxoG DNA adducts [27]. Decreased repair activity for removal of 8-hydroxyguanine adducts has been observed by homozygous mutant hOGG1 (Cys326Ser) protein [28].


## 5. Conclusion

In conclusion, we have observed a significant association of germ line mutations of OGG1 with breast cancer in Pakistani population in this study. Splice site, 3′UTR, missense, and nonsense mutations in highly conserved and functionally important domains of OGG1 protein alone or in combination with other genes of the BER pathway may contribute in the process of breast carcinogenesis, each adding a small effect on the overall cancer risk in Pakistani population. Moreover, in line with previous findings, inhibited or reduced DNA repair and enzymatic activities of OGG1 protein may potentially sensitize the tumour cells to therapeutic agents, making OGG1 an attractive molecular target in the treatment of cancer. These molecular and epidemiological findings provide evidence that OGG1, a DNA repairing gene, could prove to be a good candidate of better diagnosis, treatment, and prevention of breast cancer.



---

*Source: 690878-2015-05-19.xml*